Aquestive Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$4.03(as of Jul 10, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Aquestive Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$4.03
Ticker SymbolAQST
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees142
CountyUSA
Market Cap$398.3M
EBIDTA-40.5M
10-Day Moving Average3.60
P/E Ratio-7.10
20-Day Moving Average3.47
Forward P/E Ratio0.00
50-Day Moving Average3.07
Earnings per Share-0.58
200-Day Moving Average3.58
Profit Margin-262.96%
RSI74.38
Shares Outstanding99.33M
ATR0.21
52-Week High5.80
Volume1,001,068
52-Week Low2.12
Most Recent Support Level3.62
Book Value-60.9M
Most Recent Resistance Level3.80
P/B Ratio-6.32
Upper Keltner3.95
P/S Ratio7.10
Lower Keltner3.00
Debt-to-Equity Ratio3.95
Next Earnings Date08/12/2025
Cash Surplus50.4M
Next Ex-Dividend DateUnknown

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.